Journal Article DZNE-2023-00805

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer's disease.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2023
Nature America Inc. New York, NY

Nature medicine 29(8), 1979 - 1988 () [10.1038/s41591-023-02476-4]

This record in other databases:    

Please use a persistent id in citations: doi:

Abstract: Alzheimer's disease (AD) pathology develops many years before the onset of cognitive symptoms. Two pathological processes-aggregation of the amyloid-β (Aβ) peptide into plaques and the microtubule protein tau into neurofibrillary tangles (NFTs)-are hallmarks of the disease. However, other pathological brain processes are thought to be key disease mediators of Aβ plaque and NFT pathology. How these additional pathologies evolve over the course of the disease is currently unknown. Here we show that proteomic measurements in autosomal dominant AD cerebrospinal fluid (CSF) linked to brain protein coexpression can be used to characterize the evolution of AD pathology over a timescale spanning six decades. SMOC1 and SPON1 proteins associated with Aβ plaques were elevated in AD CSF nearly 30 years before the onset of symptoms, followed by changes in synaptic proteins, metabolic proteins, axonal proteins, inflammatory proteins and finally decreases in neurosecretory proteins. The proteome discriminated mutation carriers from noncarriers before symptom onset as well or better than Aβ and tau measures. Our results highlight the multifaceted landscape of AD pathophysiology and its temporal evolution. Such knowledge will be critical for developing precision therapeutic interventions and biomarkers for AD beyond those associated with Aβ and tau.

Keyword(s): Alzheimer Disease: cerebrospinal fluid (MeSH) ; Humans (MeSH) ; Alzheimer Disease: pathology (MeSH) ; Proteomics (MeSH) ; Amyloid beta-Peptides: metabolism (MeSH) ; tau Proteins: metabolism (MeSH) ; Neurofibrillary Tangles: pathology (MeSH) ; Biomarkers: metabolism (MeSH) ; Alzheimer Disease: genetics (MeSH) ; Alzheimer Disease: physiopathology (MeSH) ; Male (MeSH) ; Female (MeSH) ; Adult (MeSH) ; Middle Aged (MeSH) ; Mutation (MeSH) ; Age of Onset (MeSH) ; SMOC1 protein, human ; Amyloid beta-Peptides ; tau Proteins ; Biomarkers

Classification:

Contributing Institute(s):
  1. Molecular Neurodegeneration (AG Haass)
  2. Cell Biology of Neurological Diseases (AG Jucker)
Research Program(s):
  1. 352 - Disease Mechanisms (POF4-352) (POF4-352)
Experiment(s):
  1. Longitudinal Study on Dominantly Inherited Alzheimer's Disease

Appears in the scientific report 2023
Database coverage:
Medline ; Creative Commons Attribution CC BY 4.0 ; OpenAccess ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 80 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > TÜ DZNE > TÜ DZNE-AG Jucker
Institute Collections > M DZNE > M DZNE-AG Haass
Full Text Collection
Public records
Publications Database

 Record created 2023-08-17, last modified 2024-01-12


OpenAccess:
Download fulltext PDF Download fulltext PDF (PDFA)
External link:
Download fulltextFulltext by Pubmed Central
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)